Overview

Hidradenitis Suppurativa Study of Izokibep

Status:
Recruiting
Trial end date:
2025-12-02
Target enrollment:
Participant gender:
Summary
Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin 17A, to which it binds with high affinity. This study investigates izokibep in subjects with active Hidradenitis Suppurativa (HS), including tumor necrosis factor-alpha inhibitor (TNFi) naïve subjects, and those who had an inadequate response or intolerance to TNFi, or for whom TNFi is contraindicated.
Phase:
Phase 3
Details
Lead Sponsor:
ACELYRIN Inc.